A lot of money has been wasted on pursuing so many indications with failed trials. It would have been better to do a a proper phase 2 trial on aGVHD, demonstrate efficacy and then a proper phase 3 RCT trial that would have convinced the FDA. Once that was established with revenues choose another indication. The scatter gun failed phase 2 followed by failed phase 3 approach justified by "lots of biotechs lose a billion dollars get used to it" seems a bit cavalier.
CEO Itescu needs to go, page-270
-
- There are more pages in this discussion • 638 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
88.5¢ |
Change
-0.085(8.76%) |
Mkt cap ! $1.010B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 95.0¢ | 88.0¢ | $9.657M | 10.58M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 140818 | 88.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 89.0¢ | 3680 | 1 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |